ClinicalTrials.gg
Not yet recruitingNCT07202455ENADAUpdated Dec 23, 2025

Effect of Early Neuromodulation Coupled With Rehabilitation on the Prevention of Post-stroke Pain

An interventional study of Active tDCS and Sham tDCS in Stroke, Neuropathic Pain and Central Post Stroke Pain, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stroke by University Hospital, Clermont-Ferrand — 2 open to participants now, 2 under way, none of them phase 3. Stroke · University Hospital, Clermont-Ferrand.

Started
2026
the only one that year
No phase
7 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Stroke by University Hospital, Clermont-Ferrand, this one is the only one that started in 2026, is one of 7 with no phase, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

2 of the 11 studies in Stroke by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stroke by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

This is a prospective clinical study to evaluate the efficacy of tDCS stimulation, coupled with conventional rehabilitation, on the development of post-stroke neuropathic pain.

The study involves a double-blind, randomized, sham-controlled experimental protocol involving 2 parallel groups with patients allocated according to a Fleming design (40 patients in the active group, 20 patients in the control group).

The study is aimed at sub-acute post-stroke patients. After recruitment, they will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on/off ramp of 0.1 mA/s). For the control group, stimulation will stop after the current ramp.

Read the detailed description

Selection: during hospitalization in the neurology department of Clermont-Ferrand University Hospital, the principal investigator will propose that eligible patients take part in the ENADA study. If the patient agrees, an inclusion visit (E1) will be scheduled by the inclusion center. All these patients will have had an MRI recording as part of routine post-stroke practice.

Inclusion (E1 visit): A new background check and inclusion/non-inclusion criteria will be carried out. Once the patient has signed the study consent form, he or she will complete the self-questionnaires (VAS pain intensity, VAS pain affectivity, DN4, NPSI, BPI, HAD, diagram showing hypoesthetic areas, EQ-5D). The evaluation will also include FMA-UE test, the modified Ashworth scale and sensory thresholds.

Randomization: Patients will be randomized to the active or placebo group.

Protocol: 10 stimulation sessions, spread over a maximum of 21 consecutive working days.

Active and sham tDCS sessions are identical, double-blind. Stimulation by tDCS takes place during a physiotherapy, occupational therapy or speech therapy session. After installation, stimulation lasts 20 minutes. Stimulation is delivered at an intensity of 2 mA, with a ramp for the onset and disappearance of the current. Sham stimulation stops after the onset ramp, ensuring blindness for the patient, who may feel a slight tingling sensation during this phase. Patients will complete a pain intensity VAS and an affective pain VAS before and after each tDCS stimulation.

Post-protocol visit (visit E2): this visit is scheduled 7 days after the 10th and last stimulation session. It is carried out by the principal investigator at Clermont-Ferrand University Hospital.

An MRI recording is scheduled for this visit. Patients will fill in follow-up self-questionnaires (pain intensity VAS, affective pain VAS, DN4, NPSI, BPI, HAD, diagram showing hypoesthetic areas, EQ-5D), as well as their overall impression of change (PGIC score) and their impression of change on motor and sensory aspects. The evaluation will also include FMA-UE test and the modified Ashworth scale. The quality of blinding will be assessed at visit E2 by asking the patient's impression of the treatment he or she has received and of the presumed allocation (Bang blinding index).

End-of-study visit (E3 visit): this visit is scheduled at 6 months post-stroke. It is conducted by the principal investigator at the Clermont-Ferrand University Hospital.

The same assessments are carried out as at the previous visit, as well as the evaluation of sensory thresholds. In addition, the presence of neuropathic pain (yes/no), the primary endpoint, was assessed after clinical and instrumental evaluation. The presence of non-neuropathic pain (yes/no) is also assessed.

03

Conditions studied

  • Stroke
  • Neuropathic Pain
  • Central Post Stroke Pain

Keywords

  • neuropathic pain
  • prevention
  • stroke
  • central post stroke pain
  • neuromodulation
  • tDCS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Ischemic or hemorrhagic stroke confirmed by MRI or scanner
  • Lesion(s) in somato-sensory areas (i.e. mainly in: the pons, thalamus, internal capsule, basal ganglia and operculo-insular regions)
  • Sensory and/or motor deficit requiring rehabilitation
  • Subacute stage (7 to 45 days post-stroke)
  • No neurological deficit or chronic neuropathic pain prior to stroke
  • No neuropathic pain at inclusion
  • Patient can be followed throughout the study.
  • Information letter read and understood
  • Able to give to participate in research
  • Affiliation with a social security scheme

Exclusion criteria

Exclusion Criteria:

  • to tDCS (epilepsy/history of epilepsy, intracranial ferromagnetic material or implanted stimulator, acute eczema or irritated skin over the stimulation area)
  • Contraindication to MRI (use of a pacemaker or insulin pump, wearing of a metal prosthesis, intracerebral clip or piercing, claustrophobia)
  • Cognitive or language difficulties preventing comprehension of instructions and/or correct clinical assessment
  • Patients participating in another research protocol involving a drug in the 30 days prior to inclusion
  • Drug or psychoactive substance abuse
  • Pregnant or breast-feeding women
  • Patients under guardianship or curatorship, deprived of liberty, safeguard of justice
  • Major depression
  • Patients with Parkinson's disease
  • The presence of pre-existing lesions >1.5 cm (maximum diameter) in a cerebral area belonging to the anatomically defined sensorimotor system
  • Alcohol abuse
  • Severe psychiatric disorders (e.g., schizophrenia)
  • Any tumor disease with a of \<1 year
  • Increased intracranial pressure
  • Patients with a medical device containing electronics or conductive materials
  • Patients on continuous oxygen (system not adapted)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Active group

    Patients will receive 10 sessions of active tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up and ramp-down), in addition to conventional rehabilitation.

    Device: Active tDCS

  • Sham comparator
    Control group

    Patients will receive 10 sessions of sham tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up, stimulation stopped after the current ramp), in addition to conventional rehabilitation.

    Device: Sham tDCS

Interventions

  • DeviceActive tDCS

    Patients will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on/off ramp of 0.1 mA/s) delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.

  • DeviceSham tDCS

    Patients will receive 10 sessions of sham tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up, stimulation stopped after the current ramp), delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.

06

What researchers measure

Primary outcomes

  1. Development of neuropathic pain

    The primary endpoint is the development (yes/no) of probable or definite neuropathic pain according to IASP criteria, after clinical and instrumental assessment, at 6 months post-stroke. The presence of definite neuropathic pain will be recorded in the presence of negative sensory signs, i.e. partial or complete loss of one or more sensory modalities (e.g. light touch, cold temperature, etc.) concordant with the lesion of the somatosensory nervous system (in this case stroke, the presence of which will have been confirmed by MRI).

    Time frame: At 6 months post-stroke

Secondary outcomes

  1. Development of non-neuropathic pain

    shoulder or other joint pain, spasticity-related pain, etc.

    Time frame: At 6 months post-stroke

  2. Pain intensity

    Numeric Rating Scale (NRS) ranging from 0 (no pain) to 100 (worst pain imaginable)

    Time frame: Before the protocol, within 15 minutes before and after each tDCS session, after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  3. Affective pain experience

    Numeric Rating Scale (NRS) ranging from 0 (no affective impact of pain) to 100 (worst affective impact of pain)

    Time frame: Before the protocol, within 15 minutes before and after each tDCS session, after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  4. Presence of neuropathic pain

    Douleur Neuropathique en 4 questions (DN4)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  5. Evaluation of neuropathic pain

    Questionnaire d'évaluation des douleurs neuropathiques (NPSI)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  6. Pain assessment

    Questionnaire concis sur les douleurs (BPI)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  7. Motor function

    Fugl-Meyer Assessment - Upper extremity (FMA-UE) test, ranging from 0 (worst motor function) to 66 (correct motor function)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  8. Spasticity

    Modified Ashworth Scale (MAS), ranging from 0 (no increase in muscle tone) to 4 (affectied part rigid in flexion or extension)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  9. Anxiety and depression

    Hospital Anxiety and Depression (HAD) scale, ranging from 0 (no symptoms) to 21 (most severe symptoms)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  10. Quality of life EQ-5D

    EQ-5D scale, each item coded from 1 (no problem) to 3 (extreme problem)

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  11. Patient's impression of change

    Patient's global impression of change, impression of change in motor and sensory aspects, ranging from 1 (very significantly improved) to 7 (very significantly worsened)

    Time frame: After the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  12. Perceptual and pain hot and cold thresholds

    Thermal thresholds evaluated with a Thermotest, in the area with the most pronounced sensory symptoms and the contralateral similar area

    Time frame: Before the protocol and at six months post-stroke

  13. Bang Blinding Index

    Patient's impression of being in the active or control group, each patient report his/her impression (active group/control group/don't know) and proportions are compared between the active and control group

    Time frame: After the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

  14. Brain activity

    resting-state fMRI

    Time frame: Before and after the protocol (within 7 days after the 10th and final tDCS session) and at six months post-stroke

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2029, 39 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 39 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 1, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07202455
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Dec 23, 2025

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Xavier Moisset
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion